Wuersch, Kuno, Parrula, Cecilia, Dincer, Zuhal, de Vera Mudry, Maria Cristina, Geoly, Frank and Mysore, Jagannatha (2020) Toxicologic Pathology Forum: Opinion on Obligatory Microscopic Examination of Intermediate-Dose Groups in Toxicity Studies With Biotherapeutics in Cynomolgus Monkeys. Toxicologic Pathology, 48 (8). pp. 939-943. ISSN 15331601

Abstract

In nonrodent toxicity studies that are usually conducted in cynomolgus monkeys or beagle dogs, the added value of examining all tissues from all dose groups (current practice) versus all tissues in only control and high-dose groups and target tissues in intermediate-dose groups by default, is a subject of debate. A previous retrospective review of 325 nonrodent toxicity studies that included a limited number of biotherapeutics suggested that the evaluation of all tissues from all groups was not justified as a routine practice and recommended the examination of all tissues in control and high-dose groups and only target tissues in intermediate-dose groups. In contrast, the present retrospective review which examined 213 nonrodent studies (212 in cynomolgus monkeys and 1 in dog) from 4 multinational pharmaceutical companies (Bristol-Myers Squibb, Novartis, Pfizer Inc, and Roche) conducted only with biotherapeutics showed that restricting the microscopic examination in intermediate-dose groups to target tissues has the potential to miss findings in 6.6% of studies, possibly impacting the overall study interpretation and conclusion. In conclusion and in the opinion of the authors, all tissues from all dose groups should be examined in toxicity studies with biotherapeutics conducted in nonrodent species.

Item Type:	Article
Keywords:	biotherapeutics cynomolgus dose group dose relationship histopathology nonclinical nonrodent
Date Deposited:	30 Jan 2021 00:45
Last Modified:	30 Jan 2021 00:45
URI:	https://oak.novartis.com/id/eprint/42601